Managing Chronic Inflammation with Psoriasis

Health & Lifestyle
321

Listen to article (english)

Translate to Spanish or other 102 languages!

Although the exact cause of psoriasis is unknown, doctors consider it an immune-mediated inflammatory disease. This means that inflammation is at the root of this condition. Image for illustration purposes
Although the exact cause of psoriasis is unknown, doctors consider it an immune-mediated inflammatory disease. This means that inflammation is at the root of this condition. Image for illustration purposes

Medical News Today

- Advertisement -

Up to 3%Trusted Source of adults in the United States have psoriasis. It causes skin symptoms, such as raised plaques and discoloration, and can also affect other parts of the body, such as the joints and eyes.

Experts believe inflammation is the common factor that can affect these different areas.

Follow the link below to Medical News Today to read the full story:

- Advertisement -

https://www.medicalnewstoday.com/articles/psoriasis-and-chronic-inflammation

Information Source: https://www.medicalnewstoday.com

- Advertisement -
- Advertisement -

Latest news

- Advertisement -
Previous article
Childhood Arthritis & What you Need to Know
Next article
Physical Activity & Self-Management Education Programs for Arthritis

More Articles

STHS Behavioral’s Summer Mental Health Tips for Kids

STHS Behavioral urges families to prioritize emotional well-being by maintaining routines, encouraging social connections and fostering growth beyond the classroom.

New Insight Into the Iron-Retention Strategies of Colorectal Cancer Cells

Mega Doctor News by Michigan Medicine - University of Michigan Newswise — ANN ARBOR, Michigan...

Study: Weight Loss Drugs Cut Risk of Four Cancers by Half or More

Medical News Today The use of glucagon-like peptide-1 (GLP-1) receptor agonistTrusted Source medications continues...

FDA Approves Expanded Use of Kidney Cancer Treatment Rooted in UTSW Discovery

Belzutifan, a first-in-class drug that arose from scientific discoveries at UT Southwestern Medical Center, has been approved by the Food and Drug Administration to treat some patients with earlier stage kidney cancers in combination with an immunotherapy drug. This move marks the latest expansion of belzutifan’s indications after it was originally approved in 2021.
- Advertisement -